CohBar Inc. (NASDAQ: CWBR) Attends 31st Annual ROTH Conference
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company focused on the research and development of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction. For more information, visit the company's website at www.cohbar.com.…







